The acquisition of software assets (Klone brand) by a biotech company is an unusual strategic pivot for a micro-cap pharma. The 12-month lockup on the warrant shares prevents immediate overhang. Monitor for any subsequent 8-K filings regarding the software's integration or any revenue generated from the acquired assets.
Price Chart
Executive Summary
Silo Pharma acquired software, technology, and related intellectual property (the 'Klone' brand web-based tools) from Norsight Consulting Inc. in exchange for a warrant to purchase up to 300,000 shares of SILO common stock at $1.51 per share, exercisable from April 1, 2027 to September 30, 2031. The warrant includes a cashless exercise feature and a 4.99% beneficial ownership limitation, and the underlying shares are subject to a 12-month lockup. This is a non-cash, non-dilutive (until exercise) acquisition of software assets by a micro-cap biotech company, representing a strategic pivot or expansion into software tools.
Key Facts
- Silo Pharma acquired software, technology, and related IP (Klone brand) from Norsight Consulting Inc.
- Purchase price: warrant to purchase up to 300,000 shares of SILO common stock at $1.51/share.
- Warrant exercisable from April 1, 2027 to September 30, 2031 (5-year term).
- Warrant includes cashless exercise feature and 4.99% beneficial ownership limitation (can be increased to 9.99% with 61 days' notice).
- Shares issuable upon warrant exercise are subject to a 12-month lockup from October 1, 2026.
- Warrant issued in reliance on Section 4(a)(2) of the Securities Act (unregistered sale).
- No cash consideration was paid; the deal is non-dilutive until the warrant is exercised.
Financial Impact
No cash consideration; the deal is non-cash and non-dilutive until the warrant is exercised. The warrant has a $1.51 exercise price, representing a potential future dilution of up to 300,000 shares if exercised.
Risk Factors
- The acquired software assets may not generate revenue or have a clear path to commercialization.
- The warrant's cashless exercise feature could still lead to dilution if the stock price appreciates above $1.51.
- The deal is a non-cash, non-dilutive, but the strategic rationale for a biotech acquiring software is unclear.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-106435 |
| Document: ea030759801ex10-1.htm | 0001213900-26-106435 |
| Document: ea0307598-8k_silo.htm | 0001213900-26-106435 |
| Document: 0001213900-26-106435-index-headers.html | 0001213900-26-106435 |
| Document: 0001213900-26-106435-index.html | 0001213900-26-106435 |
| Document: 0001213900-26-106435.txt | 0001213900-26-106435 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $1.20 | awaiting T+60 | — | $1.16 (−3.33%) |
Oct 2, 2026 25d ago | 8-K | $1.49 | awaiting T+60 | — | $1.16 (−22.15%) |
Sep 18, 2026 5w ago | Press Release | $1.84 | awaiting T+60 | — | $1.16 (−36.96%) |
Aug 7, 2026 11w ago | EFFECT | $3.74 | awaiting T+60 | — | $1.16 (−68.94%) |
Jul 14, 2026 15w ago | Press Release | $5.13 $1.44 | ▼ −71.93% | ▼ −75.31% | $1.16 (−77.39%) |
Jun 30, 2026 17w ago | DEFA14A | $6.21 $1.77 | ▲ +71.50% | ▲ +75.06% | $1.16 (+81.32%) |
Jun 3, 2026 20w ago | 8-K | $6.11 $2.54 | ▼ −58.43% | ▼ −60.31% | $1.16 (−81.01%) |
Jun 1, 2026 21w ago | 8-K | $4.99 $2.59 | ▼ −48.09% | ▼ −49.32% | $1.16 (−76.75%) |
Apr 29, 2026 25w ago | Press Release | $6.74 $4.47 | ▼ −33.63% | ▼ −37.74% | $1.16 (−82.78%) |
Apr 22, 2026 26w ago | Press Release | $7.11 $4.70 | ▼ −33.90% | ▼ −38.91% | $1.16 (−83.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers